MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Immunocore Holdings PLC ADR

Închisă

34.78 -1.17

Rezumat

Modificarea prețului

24h

Curent

Minim

34.11

Maxim

35.03

Indicatori cheie

By Trading Economics

Venit

29M

5M

Vânzări

9.8M

94M

Marjă de profit

5.35

Angajați

493

EBITDA

13M

-3.6M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+77.09% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

125M

1.6B

Deschiderea anterioară

35.95

Închiderea anterioară

34.78

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Immunocore Holdings PLC ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 iul. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

FCC Approves U.S. Cellular Sale to T-Mobile

11 iul. 2025, 17:28 UTC

Principalele dinamici ale pieței

SharpLink Gaming Gains on Ethereum Purchase

11 iul. 2025, 16:57 UTC

Câștiguri

BASF Cuts Outlook on Global Economy Uncertainty

11 iul. 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 iul. 2025, 19:46 UTC

Achiziții, Fuziuni, Preluări

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 iul. 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 iul. 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 iul. 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 iul. 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 iul. 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 iul. 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11 iul. 2025, 16:42 UTC

Câștiguri

BASF Cuts Outlook on Global Economic Uncertainty

11 iul. 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 iul. 2025, 16:05 UTC

Câștiguri

BASF Will Publish Half-Year Results on July 30

11 iul. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11 iul. 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 iul. 2025, 16:03 UTC

Câștiguri

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 iul. 2025, 16:02 UTC

Câștiguri

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 iul. 2025, 16:01 UTC

Câștiguri

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 iul. 2025, 16:00 UTC

Câștiguri

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 iul. 2025, 15:59 UTC

Câștiguri

BASF Cuts 2025 Earnings View

11 iul. 2025, 15:58 UTC

Câștiguri

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 iul. 2025, 15:57 UTC

Câștiguri

BASF 2Q EBIT Before Special Items EUR810M

11 iul. 2025, 15:54 UTC

Câștiguri

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 iul. 2025, 15:54 UTC

Câștiguri

BASF 2Q Sales Fell 2.1% on Year

11 iul. 2025, 15:53 UTC

Câștiguri

BASF 2Q Sales EUR15.77B

11 iul. 2025, 15:52 UTC

Câștiguri

BASF: This Was in Line With Consensus Estimates

11 iul. 2025, 15:52 UTC

Câștiguri

BASF 2Q Ebitda Before Special Items EUR1.77B

11 iul. 2025, 15:49 UTC

Câștiguri

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 iul. 2025, 15:41 UTC

Market Talk

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Comparație

Modificare preț

Immunocore Holdings PLC ADR Așteptări

Obiectiv de preț

By TipRanks

77.09% sus

Prognoză pe 12 luni

Medie 62.78 USD  77.09%

Maxim 100 USD

Minim 31 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruImmunocore Holdings PLC ADR - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

7

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

27.895 / 30.16Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.